首页> 美国卫生研究院文献>Scientific Reports >Novel conjugates of aminoadamantanes with carbazole derivatives as potential multitarget agents for AD treatment
【2h】

Novel conjugates of aminoadamantanes with carbazole derivatives as potential multitarget agents for AD treatment

机译:氨基金刚烷与咔唑衍生物的新型共轭物可作为潜在的多靶点药物用于AD治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A new group of compounds, promising for the design of original multitarget therapeutic agents for treating neurodegenerative diseases, based on conjugates of aminoadamantane and carbazole derivatives was synthesized and investigated. Compounds of these series were found to interact with a group of targets that play an important role in the development of this type of diseases. First of all, these compounds selectively inhibit butyrylcholinesterase, block NMDA receptors containing NR2B subunits while maintaining the properties of MK-801 binding site blockers, exert microtubules stabilizing properties, and possess the ability to protect nerve cells from death at the calcium overload conditions. The leading compound C-2h has been shown the most promising effects on all analyzed parameters. Thus, these compounds can be regarded as promising candidates for the design of multi-target disease-modifying drugs for treatment of AD and/or similar neuropathologies.
机译:合成并研究了一组新的化合物,这些化合物有望基于氨基金刚烷和咔唑衍生物的缀合物设计用于治疗神经退行性疾病的原始多靶标治疗剂。发现这些系列的化合物与一组靶标相互作用,这些靶标在这类疾病的发展中起重要作用。首先,这些化合物选择性抑制丁酰胆碱酯酶,阻断含有NR2B亚基的NMDA受体,同时保持MK-801结合位点阻滞剂的特性,发挥微管稳定特性,并具有在钙超载条件下保护神经细胞免于死亡的能力。领先的化合物C-2h已显示出对所有分析参数的最有希望的影响。因此,这些化合物可以被认为是设计用于治疗AD和/或类似神经病理学的多靶点疾病减轻药物的有希望的候选物。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号